Biomaterials must meet certain fundamental requirements for their usage in living beings, such as biocompatibility, bifunctionality, and sterilizability, without having chemical and structural changes. The biocompatibility of poly(lactic acid) (PLA) films, shaped by compression, was evaluated after sterilization by ethylene oxide by a histological in vivo test with Wistar rats and cytotoxicity in cell adhesion in vitro. The cytotoxicity test was performed by the reduction of tetrazolium salt (MTT). Thermal and chemical changes in PLA films concerning the proposed sterilization process and characteristics were not observed to evidence polymer degradation due to sterilization. The analysis of the cytotoxicity by the MTT method has shown that the sterilized PLA films are not cytotoxic. The adhesion and proliferation of fibroblasts on PLA films were homogeneously distributed over the evaluation period, showing an elongated appearance with unnumbered cytoplasmic extensions and cell-cell interactions. By examining the biocompatibility in a histological study, a mild tissue inflammation was observed with the presence of fibrosis in the samples that had been exposed for 21 days in the rats’ bodies. PLA films sterilized with ethylene oxide did not exhibit cell adhesion in vitro and toxicity to the surrounding tissue in vivo and they may be used in future in vivo testing, according to histological findings in Wistar rats in the present study.

Polymers are often used to coat tablets for controlled drug release. The purpose of this study is to evaluate the solubility of the HPMC and PVA blend compared to isolated polymers in solutions with a pH of biological fluids (6 and 1.2) and the dissolution of capsules obtained using theophylline granules produced with the HPMC/PVA 25/75 blend as a matrix and as coating. HPMC is completely solubilized in the medium that simulates the pH of the stomach and intestine, and PVA is the polymer that allows controlling the solubility of the blend in the medium, with a differents pH. The dissolution time was monitored by UV absorbance with maximum theophylline at 269 nm. The theophylline was released immediately in the granules, and in the capsules 78.4% after 30 minutes and 97.4%, after 120 minutes. Thus, PVA can potentially control the drug solubilization, contributing to obtaining modified release systems.

The use of nanocellulose in pharmaceutics is a trend that has emerged in recent years. Its inherently good mechanical properties, compared to different materials, such as its high tensile strength, high elastic modulus and high porosity, as well as its renewability and biodegradability are driving nanocellulose’s industrial use and innovations. In this sense, this study aims to conduct a search of patents from 2011 to 2023, involving applications of nanocellulose in pharmaceuticals. A patent search was carried out, employing three different patent databases: Patentscope from World Intellectual Property Organization (WIPO); Espacenet; and LENS.ORG. Patents were separated into two main groups, (i) nanocellulose (NC) comprising all its variations and (ii) bacterial nanocellulose (BNC), and classified into five major areas, according to their application. A total of 215 documents was retrieved, of which 179 were referred to the NC group and 36 to the BNC group. The NC group depicted 49.7%, 15.6%, 16.2%, 8.9% and 9.5% of patents as belonging to design and manufacturing, cell culture systems, drug delivery, wound healing and tissue engineering clusters, respectively. The BNC group classified 44.5% of patents as design and manufacturing and 30.6% as drug delivery, as well as 5.6% and 19.4% of patents as wound healing and tissue engineering, respectively. In conclusion, this work compiled and classified patents addressing exclusively the use of nanocellulose in pharmaceuticals, providing information on its current status and trending advancements, considering environmental responsibility and sustainability in materials and products development for a greener upcoming future.

Given the global panorama of demands in the health area, the development of biomaterials becomes irreducible for the maintenance and/or improvement in the quality of life of the human being. Aiming to reduce the impacts related to infections in the healing processes of the dermal structure, the present work proposes the development of polydimethylsiloxane (PDMS) based membranes with the incorporated polyhexamethylenebiguanide (PHMB) antimicrobial agent. In the present study, the antimicrobial and antibiofilm properties of polydimethylsiloxane (PDMS) films incorporated with 0.1, 0.3, and 0.5% (w/w) of polyhexamethylene biguanide (PHMB) were evaluated, aiming the development of a protective biomaterial that avoids cutaneous infections from the autochthonous and allochthonous microbiota. The disk diffusion of PHMB-loaded PDMS has shown the growth inhibition of Escherichia coli (ATCC 9637), Pseudomonas aeruginosa (ATCC 27953), Acinetobacter baumannii (ATCC 19606), Staphylococcus aureus (ATCC 6538), Staphylococcus epidermidis (ATCC 12228), Streptococcus pyogenes (ATCC 19615), Bacillus subtilis (ATCC 6633) and also yeast-like fungi Candida albicans, all microorganisms found on the epidermal surface. Likewise, the present study demonstrated low cytotoxicity of the PHMB-loaded PDMS on HaCaT and L929 cells at lower concentrations (0.1% w/w), indicating the possibility of using the developed material as a dressing for wounds, burns, and post-surgical procedures.

The reductionin zinc oxide (ZnO) content in elastomeric compositions has become a subject due to the deleterious effect of zinc ions on aquatic organisms. The purpose of this study was to develop elastomeric compositions containing 0, 1, 3 and 5 phr of ZnO aiming at assessing the influence of the different contents on the rheometric, mechanical and thermal properties. The release of the zinc (Zn) content by leaching, at each step of the production and after the ageing was also assessed. All ZnO-containing compounds had similar rheometric, thermal and mechanical properties. Also, during and after exposure to accelerated ageing the released contents were similar for all compositions regarding the residual ZnO percent. In conclusion, the utilization of the 3 phr ZnO content is viable for the replacement of the usual amount employed.